Ellie Leick


Navigating COVID-19 Challenges to Provide Optimal Cancer Care

April 26th 2020

Gilberto De Lima Lopes, MD, discusses the impact of COVID-19 on his practice and how he is coping with the changes caused by the pandemic.

Transplant Considerations in Hematologic Malignancies in Light of COVID-19

April 20th 2020

Naval G. Daver, MD, discusses the impact of COVID-19 on stem cell transplant for patients with hematologic malignancies and other measures put into place to prevent patients from infection.

Expert Highlights Benefit of PARP Inhibitors in BRCA+ Breast Cancer and Potentially Beyond

April 18th 2020

Melinda L. Telli, MD, discusses the role of PARP inhibition in the treatment of patients with breast cancer who harbor the BRCA mutations and ongoing research efforts seeking to expand their use beyond this setting.

Novel Therapies Expand Options in Melanoma, But Surgery Retains Role

April 16th 2020

Omid Hamid, MD, discusses emerging treatment approaches, the role of surgery, and ongoing research efforts in melanoma.

Stem Cell Mobilization Strategies Call for Careful Consideration in Myeloma

April 15th 2020

Shaji Kumar, MD, discusses the role of stem cell transplant in multiple myeloma, different techniques for stem cell mobilization, and remaining challenges faced with this modality.

Managing Treatment Toxicity in CML and MPNs

April 14th 2020

Jorge E. Cortes, MD, discusses managing treatment toxicities to optimize therapeutic outcomes in patients with CML and MPNs.

COVID-19 Causes Shifts in Clinical Trial Practices

April 13th 2020

Shilpa Gupta, MD, discusses the modifications made to patient care in light of the COVID-19 pandemic, the hurdles faced with clinical trials during this time, and some of the ways in which her institution is facing the virus-related challenges head-on.

COVID-19 Challenges Change Oncology Practice

April 10th 2020

Suresh S. Ramalingam, MD, FASCO, discusses the adjustments being made in cancer care due to the rapid spread of COVID-19 and treatments under development.

ADCs and Other Novel Agents Boost HER2+ Breast Cancer Paradigm

April 10th 2020

Chau T. Dang, MD, discusses recent treatment breakthroughs and emerging agents in HER2-positive breast cancer.

Cabozantinib Combinations Generate Excitement in RCC

April 8th 2020

Rana R. McKay, MD, discusses the evolving role of cabozantinib in the renal cell carcinoma treatment paradigm and the research being done examining novel combinations.

Community Oncologist Underscores Importance of Education and Collaboration

April 6th 2020

Derek Thomas, MD, discusses his experience as a community oncologist and some challenges faced in practice.

Inclusion of Geriatric Populations in Breast Cancer Research Needed to Improve Care

April 3rd 2020

Enrique Soto Pérez de Celis, MD, MSc, discusses some of the challenges of treating geriatric patients with breast cancer, emerging treatment options for this patient population, and recommendations for treating older patients.

MRD Assessment Gains Momentum in Hematologic Malignancies

April 3rd 2020

Jerald P. Radich, MD, discusses the growing importance of MRD assessment in the treatment paradigm for patients with hematologic malignancies.

Borghaei Shares Long-Term Implications of COVID-19 on Cancer Care

April 3rd 2020

Hossein Borghaei, DO, MS, discusses the impact of COVID-19 on clinical practice and projected how the virus will change practice for the better in the long term.

Pennell Shares Best Practices for Molecular Testing in Lung Cancer

March 31st 2020

Nathan Pennell, MD, PhD, offers strategies regarding molecular testing in patients with lung cancer and how to address treatment if patients are symptomatic and molecular testing results are unavailable.

Outpatient CAR T-Cell Therapy Found Safe, Effective in Large B-Cell Lymphoma

March 30th 2020

Carlos R. Bachier, MD, discusses the use of CAR T-cell therapy in the outpatient setting. He also shared insight on the evolving paradigm of graft-versus-host disease.

Optimal Management Needed for Blood Count Recovery Following CAR T-Cell Therapy

March 27th 2020

Tania Jain, MBBS, discusses blood count recovery in patients with hematology malignancies who receive CAR T-cell therapy.

Racial Disparities Reported With Quality of Care in Endometrial Cancer

March 26th 2020

Jason D. Wright, MD, discusses the findings of this trial and how practice can shift to decrease the gap between African-American and white patients with endometrial cancer.

Plasma-Based TMB May Predict Pembrolizumab Response in NSCLC

March 24th 2020

Charu Aggarwal, MD, MPH, discusses the design and findings of an analysis examining the role of TMB as a predictive biomarker for pembrolizumab-based therapy in NSCLC.

Belantamab Mafodotin Emerging as Novel Option for Relapsed/Refractory Myeloma

March 24th 2020

Sagar Lonial, MD, FACP, discusses the encouraging activity with the BCMA-targeted agent belantamab mafodotin in multiple myeloma.